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Aim. The first line treatment of patients with intermittent claudication (IC) is to prolong life via cardiac risk factor man-
agement. We aimed to compare current standards of secondary prevention with those in a previously published audit.
Methods. Risk factor data was prospectively collated on 304 consecutive new referrals attending the claudication clinic
over a 1-year period (2004/2005) and compared to the 104 patients assessed in 2000.
Results. In 2004/5 30%, (n¼ 91) of patients did not have a diagnosis of IC confirmed (p< 0.01). The use of antiplatelet
therapy remained static at 73%. Statin therapy increased in 2004/5 (62% versus 38%, p< 0.01) but blood pressure control
remained poor with 65% failing to achieve the target levels. Smoking cessation therapy continues to be offered to a minority
of patients and 17% of patients have previously undiagnosed diabetes in 2004/2005 (p-value 0.353). The number of
patients who have been advised to increase physical activity significantly has fallen from 15% to 2% in the 2004/5
(p< 0.01).
Conclusions. Difficulties exist in diagnosing intermittent claudication in primary care and cardiac risk factor manage-
ment continues to be sub-optimally managed.
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Intermittent claudication (IC) is a common and
potentially disabling disorder, which impairs quality
of life and is a marker of significant underlying
cardiovascular disease. In Western countries the inci-
dence of intermittent claudication has been shown to
range between 2% and 7% inmiddle aged populations.
In the United Kingdom, the Edinburgh Artery Survey
examined over 1500 subjects aged 55 to 74, of whom
4.5% had symptomatic claudication, and 8% had
asymptomatic disease, defined as an ankle brachial
pressure of less than 0.9.1 Patients with intermittent
claudication have been shown to have as high a risk
of developing, or dying from, coronary heart disease
as many patients surviving their first myocardial
infarction (MI).2 The Joint British recommendations
on prevention of coronary heart disease in clinical
practice, published in 1998, stated that patients with
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be managed in the same way as those with established
coronary heart disease.2 More recent reviews and
detailed guidelines from the American College of
Cardiology/American Heart Association 20063 have
also reinforced this important message.4,5 Current
guidelines state that all PVD patients should: be
prescribed aspirin; be commenced on statin therapy
providing their cholesterol level is above 3.5 mmol/l,
be screened for the presence of diabetes, and undergo
rigorous control of their blood pressure, with the
aim of achieving a systolic less than 140 mmHg and
diastolic less than 90 mmHg. For patients with
diabetes the recommended target blood pressure is
a systolic less than 130 mmHg and diastolic less than
80 mmHg. Patients should also receive lifestyle inter-
vention measures aimed at discontinuing smoking
and increasing aerobic exercise.
A previously published local audit, performed in
2000,6 identified suboptimal management of all of
these risk factors in new patients referred to the clau-
dication clinic. Efforts were made to increase the
awareness of this condition on a local level byrved.
711Completing the Audit Cycleproviding feedback to general practitioners, along
with invitations to talks held at primary care practices
on the diagnosis, prognosis and need for risk factor
management in patients with IC. This was aided by
the publication of national guidelines by Burns et al.
in the British Medical Journal.4 In order to complete
the audit loop and assess the effectiveness of this
approach we aimed to perform a further prospective
audit and to compare this data with the 2000 audit
to see if any improvement had occurred.
Methods
Data was prospectively collated on 304 consecutive
new referrals attending the claudication clinic over
a one-year period (October 2004eSeptember 2005)
using a pre-defined datasheet. A full history was
recorded, and the following risk factors were then
assessed: dyslipidaemia, hypertension, diabetes,
smoking and cessation therapy, level of exercise and
use of antiplatelet therapy (Table 1). All patients
underwent a clinical examination, which included
measurement of blood pressure and ankle brachial
pressure indices (ABPIs) performed by a fully ac-
credited vascular technologist. Those patients with
symptoms of claudication and an ABPI less than 0.9
were deemed to have peripheral vascular disease.7
Patients with a history highly suggestive of intermit-
tent claudication but with normal ABPIs underwent
testing to measure ABPI after exercise. Those patients
with an ABPI greater than 1.3 had toe pressures mea-
sured. Blood samples were taken from non-fasted
patients for random glucose, total cholesterol, urea
and electrolytes, liver function tests and full blood
count. Patients with a random glucose of greater
than 5.6 mmol/l had fasting blood glucose tests and
an oral glucose tolerance test if necessary.Statistical Analysis
Statistical analysis was performed using SPSS (Statisti-
cal Package for the Social sciences) version 14.0 for all
tests. Continuously distributed variables are expressed
as mean (standard deviations, SD) and comparisons
were made with non-paired t tests. Categorical data
were analysed with.2 A probability value of p< 0.05
was considered significant.
Results
The number of new patients who did not have a con-
firmed diagnosis of IC increased from 17% in the first
audit (21/125) to 30% (91/304) in the second (p-
value¼ 0.007). In the later audit period, 213 patients
with a confirmed diagnosis of IC attended the clinic
(Table 2). The mean index-limb ankle-brachial pres-
sure index was 0.59 (SD 0.17), which was significantly
lower than in 2000 (0.73, SD 0.19) (p-value< 0.01). The
number of patients with a history of coronary heart
disease fell from 32% in 2000 to 19% in the later audit
( p-value¼ 0.020).
Risk factor management in patients with a
diagnosis of PAD
Dyslipidaemia
The proportion of patients with intermittent claudica-
tion on statin therapy increased significantly from
38% to 62% (p-value< 0.01). The number of patients
with controlled cholesterol levels (<5 mmol/L) also
significantly improved from 35% to 58% (p-value<
0.01). In the 2000 cohort, of the 39 patients on statin ther-
apy, 47% (18) had a cholesterol level greater than
5 mmol/L (Fig. 1). In the later cohort, of the 62% (132)
patients on a statin, 25% (33) had a cholesterol level
greater than 5 mmol/L (Fig. 1).Table 1. Claudication clinic protocol
Risk factor Screening Management
Antiplatelet All patients should be on antiplatelet
therapy (unless on warfarin)
Prescribe aspirin 75 mg daily
Clopidogrel 75 mg as second line therapy
Dyslipidaemia Random cholesterol Start statin if cholesterol level is greater than 3.5 mmol/l
Inform general practitioner to monitor reduction in serum
cholesterol
Hypertension Resting blood pressure If high:
Targets: <140/90 mmHg Inform general practitioner
Diabetics <130/80 mmHg Ask patient to make appointment with practice nurse
Diabetes Random glucose >5.6 mmol/l e inform general practitioner
Patient required fasting glucose oral glucose tolerance test
Smoking Advise patient to stop Refer to nurse smoking cessation councillor
Prescribe nicotine replacement therapy
Exercise Advise patient to increase Supervised exercise programme currently not availableEur J Vasc Endovasc Surg Vol 33, June 2007
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The prevalence of previously diagnosed diabetes in
new referrals was 23% (n¼ 48) in 2004/2005 compared
to 16% (18) in the earlier cohort ( p-value 0.353). In the
later cohort, 74% (158) of patients with IC were not
known to be diabetic and had no recollection, or docu-
mentation, of a blood test. Of these 17% (n¼ 27) were
found to have previously undiagnosed diabetes. Sim-
ilarly, in 2000, previously undiagnosed diabetes was
identified in 14%.
Hypertension
The use of antihypertensive therapy increased from
43% to 62% in the later audit ( p-value< 0.01). This
also corresponded with a decrease in uncontrolled
hypertension (BP> 140/90 mmHg) from 73% to 65%
( p-value¼ 0.176). The blood pressures of the two
cohorts are shown in Fig. 2. The target BP of 130/
80 mmHg for diabetic patients was achieved only in
35% of the later cohort.
Antiplatelet therapy
In 2000, 73% of patients with intermittent claudication
were on anti-platelet therapy and this was unchanged
in 2004/2005. The prescribing of an alternative anti-
platelet to aspirin (e.g. Clopidogrel) had increased
from 7% to 10%.
Table 2. Claudicant demographics
2000 N¼ 104 2004/05 N¼ 213 p-value
Age in years (range) 70 (41e85) 68 (36e87) 0.30
Sex (M:F) 57:47 (1.21:1) 138:75 (1.84:1) 0.11
ABPI (std) 0.73 (0.19) 0.59 (0.17). <0.01
History of cardiac
disease (angina, MI,
revascularisation)
32% (n¼ 33) 19% (n¼ 41) 0.02
Hypertensive therapy 43% (n¼ 45) 62% (n¼ 131) <0.01
Known diabetic 16% (n¼ 18) 23% (n¼ 48) 0.35
Data is mean (SD) or % (number) of patients. P value- non paired
t-test or chi-squared of 2000 versus 2004/5 audit data.
Abbreviations: ABPI e ankle brachial pressure index.
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Fig. 1. Cholesterol level and statin therapy. Legend key;
Red¼No statin, Yellow¼On statin.Eur J Vasc Endovasc Surg Vol 33, June 2007Of the patients surveyed in 2000, 66% were pre-
scribed aspirin and 7% clopidogrel or warfarin. In total
73% of the 104 IC patients were on antiplatelet or anti-
coagulant medication and of the remaining 27% of
patients, 7% were aspirin intolerant and 20% had no
contraindications to the drug. Similarly in 2004/05,
63% of the 213 claudicants were prescribed aspirin
and 10% were on clopidogrel or warfarin. In 1% anti-
platelet agents were contraindicated and consequently
26% had no antiplatelet therapy.
Cigarette smoking
The number of patients with IC who admitted to
smoking was similar in the two time periods (38%
versus 36%), as was the number of ex and non-
smokers. The proportion advised to stop smoking
(85% versus 80%) also remained static. In the original
audit only 7 (18%) of the 39 smokers had been given
any further help to stop smoking. Unfortunately smok-
ing cessation help was not recorded in the later audit.
Exercise
The number of patients who recalled receiving advice
to increase physical activity significantly fell from 14%
to 2% (p-value< 0.01).
Conclusions
Overall, patients diagnosed as having PAD have a two
to three fold increased risk of cardiovascular and cere-
brovascular mortality when compared to an age and
sex matched group without PAD.8,9 This audit has
shown that well recognised cardiac risk factors in
patients with intermittent claudication continue to
be sub-optimally managed. This is disappointing
given local and national efforts to increase the aware-
ness and profile of this condition. Almost a third of
our new referrals to our speciality claudication clinic
10
0
20
30
40
50
60
70
80
Less than 140/90 Less than 140/90 140/90 or greater 140/90 or greater
2000 2004/05 2000 2004/05
BP (mmHg)
%
 o
f p
at
ie
nt
s
Fig. 2. Blood pressure. Yellow¼On antihypertensive,
Red¼No antihypertensive.
713Completing the Audit Cycledo not have PAD. Yet those who do, have more severe
disease, as shown by the significant decrease in the
ABPI.10e12 The mean index-limb ankle-brachial
pressure index was 0.59 in the later cohort (SD 0.17).
A recent community based longitudinal study of
adults aged 65 and older has shown that the all cause
cardiovascular mortality and events were consistently
higher amongst patients with an ABPI of 0.6 or less.13
Significant linear trends have been shown across ABPI
categories and cardiovascular outcome in a number of
studies14e16 and this relationship appears to be inde-
pendent of the metabolic syndrome and other major
CVD risk factors.17
In our latest audit, over a quarter of patients with
IC are still not prescribed antiplatelet therapy, despite
no apparent contra-indications, and the presence of
national guidelines since 1998 (which recommend
their routine use). Diabetes continues to remain
undiagnosed in 17% of new patients with IC, and
consequently is under treated, in the community. In
addition to random blood glucose we now routinely
measure HbA1C on all patients and recommend
further screening if the value is above 5.8%.18
Cigarette smoking is acknowledged to be ‘‘the sin-
gle most powerful risk factor associated with the aeti-
ology and clinical progression of peripheral arterial
disease’’.8 Nicotine replacement therapy (NRT) has
been available for several years and shown to be effec-
tive and capable of increasing quit rates by approxi-
mately 1.5 to 2 fold.19 Newer treatments may be
even more effective.20 Yet only a minority of smokers
in this study in the two time periods were offered ces-
sation advice or therapy. Despite the recognised
importance of exercise on cardiac risk factors and
the ability of exercise programmes to substantially in-
crease walking distance in patients with intermittent
claudication only 2% of patients in the later cohort
were correctly advised to increase their levels of phys-
ical activity.21
There have been some marginal improvements
such as a significant increase in use of statin therapy
despite a reduction in the number of patients with
documented ischaemic heart disease in the later co-
hort. However, the Heart protection study,22 which
was published after our initial audit, clearly showed
that the benefits of statins occur irrespective of the
cholesterol level. Thus all patients with IC should be
prescribed a statin providing their cholesterol level
is above 3.5 mmol. Despite this, over a third of new
patients with IC have not been started on a statin
and in those on therapy this appeared ineffective in
a quarter of patients. It is now apparent that the
benefit achieved with statin therapy is directly pro-
portional to the reduction in cholesterol.23 There hasalso been an increase use of hypertensive therapy,
yet two thirds of patients with IC in the later cohort
still had resting blood pressure recordings above the
recommended target level set by the British Society
of hypertension. In diabetic patients only 35% had
appropriate BP control (<130/80).
This study has shown that currently patients with
intermittent claudication are receiving suboptimal
secondary prevention. One of the underlying reasons
for this is likely to be the inadequate recognition and
diagnosis of intermittent claudication in the commu-
nity. This is discussed further in the article by
Schouten et al.24
References
1 FOWKES FGR, HOUSLEY E, CAWOOD EH, MACINTYRE CC, RUCKLEY CV,
PRESCOTT RJ. Edinburgh artery study: prevalence of asymptom-
atic and symptomatic peripheral arterial disease in the general
population. Int J Epidemiol 1991;20:384e392.
2 WOOD D, DURRINGTON P, POULTER N, MCINNES G, REES A, WRAY R.
Joint British Recommendations on prevention of coronary heart
disease in clinical practice. Heart 1998;80(Suppl. 2):S1eS29.
3 HIRSCH AT, HASKAL ZJ, HERTZER NR, BAKAL CW, CREAGER MA,
HALPERIN JL et al. ACC/AHA Guidelines for the management
of PAD. J Am Coll Cardiol 2006;47(6):1239e1312.
4 BURNS P, GOUGH S, BRADBURY AW. Management of peripheral
arterial disease in primary care. BMJ 2003;326:584e588.
5 DONNELLY R, YEUNG JM. Management of intermittent claudica-
tion. Eur J Vasc Endovasc Surg 2002;23(2):100e107.
6 CASSAR K, COULL R, BACHOO P, MACAULAY E, BRITTENDEN J. Manage-
ment of secondary risk factors in patients with intermittent clau-
dication. Eur J Vasc Endovasc Surg 2003;26(3):262e266.
7 TASC working group. Management of peripheral arterial dis-
ease, Section B; Intermittent claudication. J Vasc Surg 2000;31(1,
Part 2):S54eS134.
8 DORMANDY JA, HEECK L, VIG S. The natural history of claudica-
tion: risk to life and limb. Semin Vasc Surg 1999;12(2):123e137.
9 FOWKES FG. Epidemiology of atherosclerotic arterial disease in
the lower limbs. Eur J Vasc Surg 1988;2(5):283e291.
10 NEWMAN AB, SHEMANSKI L, MANOLIO TA, CUSHMAN M,
MITTELMARK M, POLAK JF et al. Ankle-arm index as a predictor
of cardiovascular disease and mortality in the Cardiovascular
Health Study. The Cardiovascular Health Study Group. Arterios-
cler Thromb Vasc Biol 1999;19(3):538e545.
11 MOHLER ER. Peripheral arterial disease: identification and impli-
cations. Arch Intern Med 2003;163(19):2306e2314.
12 DONNELLY R. Assessment and management of intermittent clau-
dication: importance of secondary prevention. Int J Clin Pract
Suppl 2001;119:2e9.
13 O’HARE AM, KATZ R, SHLIPAK MG, CUSHMAN M, NEWMAN AB.
Mortality and cardiovascular risk across the ankle-arm index
spectrum: results from the Cardiovascular Health Study. Circula-
tion 2006;113(3):388e393.
14 LEE AJ, PRICE JF, RUSSELL MJ, SMITH FB, VAN WIJK MC, FOWKES FG.
Improved prediction of fatal myocardial infarction using the
ankle brachial index in addition to conventional risk factors:
the Edinburgh Artery Study. Circulation 2004;110(19):3075e3080.
15 ZHENG ZJ, SHARRETT AR, CHAMBLESS LE, ROSAMOND WD, NIETO FJ,
SHEPS DS et al. Associations of ankle-brachial index with clinical
coronary heart disease, stroke and preclinical carotid and popli-
teal atherosclerosis: the Atherosclerosis Risk in Communities
(ARIC) Study. Atherosclerosis 1997;131(1):115e125.
16 ABBOTT RD, PETROVITCH H, RODRIGUEZ BL, YANO K, SCHATZ IJ,
POPPER JS et al. Ankle/brachial blood pressure in men >70 yearsEur J Vasc Endovasc Surg Vol 33, June 2007
714 A. M. Wilson et al.of age and the risk of coronary heart disease. Am J Cardiol 2000;
86(3):280e284.
17 WILD SH. Low ankle-brachial pressure index predicts increased
risk of cardiovascular disease independent of the metabolic
syndrome and conventional cardiovascular risk factors in
the Edinburgh Artery Study. Diabetes Care 2006;29(3):637e
642.
18 BELCH JJF, TOPOL EH, AGNELLI C, BERTRAND M, CALIFF RM,
CLEMENT DL et al. Critical issues in peripheral arterial disease
detection and management: a call to action. Arch Intern Med
2003;163:884e892.
19 SILAGY C, LANCASTER T, STEAD L, MANT D, FOWLER G. Nicotine
replacement therapy for smoking cessation. Cochrane Database
Syst Rev 2004;(Issue 3). doi:10.1002/14651858.CD000146.pub2
Art. No.: CD000146.
20 CAHILL K, STEAD L, LANCASTER T. Nicotine receptor partial ago-
nists for smoking cessation. Cochrane Database Syst Rev 2007;Jan
24(1):CD006103.Eur J Vasc Endovasc Surg Vol 33, June 200721 LENG GC, FOWLER B, ERNST E. Exercise for intermittent claudica-
tion. Cochrane Database Syst Rev 2000;(Issue 2). doi:10.1002/
14651858.CD000990. Art. No.: CD000990.
22 Heart Protection Study Collaborative Group. MRC/BHF Heart
Protection Study of cholesterol lowering with Simvastatin I 20,
536 high risk individuals: a randomised placebo controlled trail.
Lancet 2002;360(9326): 7e22.
23 BAIGENT C, KEECH A, KEARNEY PM, BLACKWELL L, BUCK G,
POLLICINO C et al. Cholesterol Treatment Trialists’ (CTT) Collabo-
rators. Efficacy and safety of cholesterol-lowering treatment:
prospective meta-analysis of data from 90,056 participants in
14 randomised trials of statins. Lancet 2005;366(9493):1267e1278.
24 SCHOUTEN O, HOEKS SE, BAX JJ, POLDERMANS D. Cardiac risk
prevention in patients with intermittent claudication. Eur J
Vasc Endovasc Surg 2007;33:715e716.
Accepted 12 December 2006
Available online 28 February 2007
